My Newsfeed

FY21 was a tough year for automobile original equipment manufacturers (or auto OEMs) due to the pandemic and lockdowns. However, it was a good year for some auto OEMs' executives. Three of the top four listed two-wheeler makers' Managing Directors' (MD) remuneration ratios jumped in FY21 (The remuneration ratio is the ratio of the salary of a company's top management to the median employee's).  

As per Eicher Motors' annual report,  MD Siddhartha Lal's salary was Rs 21.1 crore in FY21, or 340 times the salary of the median employee. This was an increase from 311 times the median salary in FY20. Meanwhile, Eicher Motors' net profits in FY21 fell by 26%.

Rajiv Bajaj, MD of Bajaj Auto, received an annual salary of Rs 40.5 crore (621 times the median salary), and Pawan Munjal received an annual salary of Rs 86.9 crore (826 times the median salary). Bajaj Auto and Hero MotoCorp's FY21 net profits fell by 7% and 20%, respectively.

1. Adani Transmission: This power transmission company’s stock rose 74.7% over the last month and is currently the most overbought stock out of the Nifty500 stocks. It is strongly overvalued according to technical indicators like RSI over 70 and MFI and is trading above all the simple moving averages. This company’s shares are the best performing in the Nifty 500.

2. AU Small Finance Bank: This small finance bank has seen high level exits over the past few months, and now its head of internal audit Sumit Dhir resigned for personal reasons. The company’s management clarified that it is still in discussions with him to retain his services. This dragged the company’s stock down by 12% on Tuesday as investors were jittery about another high level exit after the bank’s Chief Risk Officer Alok Gupta quit in July, a few months after taking up his position. The bank said there have been no other exits from top management apart from these two.

3. PI Industries: This agrochemical company has impressed analysts with six brokerages upgrading their target prices for the company’s shares of the past one month. In Q1FY22, the company posted a 12.6% rise in revenues to Rs 1,194 crore and net profit was up 22.3% YoY to Rs 187.2 crore. On a sequential basis, revenues were flat, and profits rose by 4.1.%  Analysts are enthused by the company’s foray into the pharmaceutical space by acquiring Ind-Swift Laboratories’ active pharmaceutical ingredients business for nearly Rs 1,530 core. 

4. Infibeam Avenues: This fintech company’s rose nearly 19% and ended trade at Rs 47.35 and saw its weekly volumes rise nearly four times its weekly average of 82 lakh shares. This is a stock volatile over the past 4-5 months as it has hovered between Rs 39-55 for the past one year, with many ups and downs. The stock crossed all its simple moving averages on Tuesday.

5. Max Healthcare Institute: This hospital chain company’s stock rose nearly 15% in two sessions at the end of Tuesday and touched a new 52-week high of Rs 398.85, before ending at Rs 386.10. The company announced on Friday, after market hours, that its subsidiary bought the rights to develop a 500-bed hospital at Saket in South Delhi. The land on which the hospital will be built is situated between two of its existing hospitals in that area. Once all its facilities are integrated in Saket, Max Healthcare will have amongst the largest healthcare complexes in Asia with an over 2,300 bed integrated facility in Saket by 2024.

Every week, Trendlyne picks five interesting buy calls made by analysts. 

1) Steel Strip Wheels: "Exponential growth on the anvil," is what Axis Direct analysts say about this auto ancillary company, giving it an upside of 13%+ on a target price of Rs 2122. "We continue to like the growth story of the company driven by increasing contribution from the PV exports and Al-alloy wheels," analyst Sneha Prashant writes, "Furthermore, the company is positive about the domestic revival of the CV industry which has been down for the past two years. The company envisages the CV industry to contribute about Rs 500-800 Cr to the topline as the cycle turns around."

2) P&G Health: This pharma and OTC company gets a thumbs up from ICICI Direct analysts, with an upside of 18.3% on a target price of Rs. 6555. PGHL, previously known as Merck, has multiple legacy brands in its stable including Seven Seas. "The key differentiator for PGHL is that its core category is Vitamins/Minerals/Supplements," analysts Siddhanth Khandekar and Mitesh Shah write, "which, as a therapeutic category, is likely to be rediscovered due to increased awareness post the current pandemic." Volatility in margins, they note, remains a key risk. 

3) Bajaj Finance: A former multibagger is back in the good books for Motilal Oswal, with analysts noting a key event for this NBFC: Bajaj Finserv has got an in-principle approval from SEBI for sponsoring a Mutual Fund (MF). This, analysts Abhijit Tibrewal and team note, is likely to benefit the entire BajFin group, and they give Bajaj Finance an upside of 10.5% on a target price of Rs. 7,700. "Increasing per capita income, the gradual financialization of savings, a growing awareness with targeted marketing campaigns such as ‘Mutual Funds Sahi Hai’, and improving reach with digital platforms, will lead to strong AUM growth ahead."

4) Cadila Healthcare: The approval of Cadila Healthcare's needle-less ZyCov-D Covid19 vaccine has triggered a buy call from Prabhudas Lilladhar, with an upside of 26%+ on a share price of Rs.695. "Thermo-stability (2-8 degree temperature for storage) of the vaccine helps in easing storage and transportation costs," analysts Surajit Pal and Akshaya Shinde write, "Stock filling of the vaccine and commercial supply across India will commence in Oct’21, with an annual manufacturing capacity of 100-120mn doses from the newly built vaccine plant."

5) Transpek Industry: This chemicals company has caught the eye of analysts at BPWealth, with an upside of 32%+ on a target price of Rs. 2714. "A long-term contract with an MNC client helped the company deliver stellar growth in topline and bottom-line in FY19 and FY20, resulting in higher sales concentration from the polymer business," they say. "Management is looking to reduce this dependence over 2-3 years, "by launching 4-5 new products and increasing applications of existing products in non-polymer segments (mainly pharma and agrochemicals)."

See all analyst buy calls here.